Literature DB >> 2470663

Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies.

A M Emslie-Smith1, K Arahata, A G Engel.   

Abstract

Major histocompatibility complex class I (MHC-I) expression on target cells is a prerequisite for antigen-specific T cell-mediated cytotoxicity (TCMC). Enhanced MHC-I expression has been attributed to interferons (IFNs) released from inflammatory cells. In previous studies, we found evidence of TCMC (invasion of non-necrotic muscle fibers by cytotoxic T cells) in polymyositis (PM) and in inclusion body myositis (IBM). We occasionally found evidence of TCMC in Duchenne dystrophy (DD) but not in dermatomyositis (DM). This study examines the relationships between TCMC, MHC-I expression, and IFN immunoreactivity in these diseases and normal controls. In controls, reactivity for MHC-I was confined to blood vessels. In all diseases, regenerating fibers expressed MHC-I. In IBM, PM and DD, all nonnecrotic muscle fibers invaded by CD8+ cells and some adjacent fibers expressed MHC-I. In DM, myriad muscle fibers expressed MHC-I but none were invaded by CD8+ cells. In all diseases, only a few mononuclear cells and no muscle fiber surfaces were immunoreactive for IFNs. We conclude that MHC-I expression on muscle fibers is necessary but not sufficient for TCMC in myopathy; that the biological significance of increased MHC-I expression in DM remains undefined; and that currently available and appropriately controlled immunocytochemical methods show no relationship between increased MHC-I expression on muscle fibers and local IFN synthesis by mononuclear cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2470663     DOI: 10.1016/0046-8177(89)90128-7

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  82 in total

1.  Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies.

Authors:  K Nagaraju; N Raben; L Loeffler; T Parker; P J Rochon; E Lee; C Danning; R Wada; C Thompson; G Bahtiyar; J Craft; R Hooft Van Huijsduijnen; P Plotz
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

2.  Induction of HLA-DR expression on human myoblasts with interferon-gamma.

Authors:  R Hohlfeld; A G Engel
Journal:  Am J Pathol       Date:  1990-03       Impact factor: 4.307

Review 3.  Polymyositis, invasion of non-necrotic muscle fibres, and the art of repetition.

Authors:  Gerald J D Hengstman; Baziel G M van Engelen
Journal:  BMJ       Date:  2004-12-18

Review 4.  Advances in the immunobiology and treatment of inflammatory myopathies.

Authors:  Marinos C Dalakas
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592

Review 5.  Immunobiology of Inherited Muscular Dystrophies.

Authors:  James G Tidball; Steven S Welc; Michelle Wehling-Henricks
Journal:  Compr Physiol       Date:  2018-09-14       Impact factor: 9.090

Review 6.  Immunotherapy of myositis: issues, concerns and future prospects.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Rheumatol       Date:  2010-02-02       Impact factor: 20.543

7.  X-linked vacuolated myopathy : TNF-alpha and IFN-gamma expression in muscle fibers with MHC class I on sarcolemma.

Authors:  K Rouger; J P Louboutin; M Villanova; Y Cherel; M Fardeau
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

Review 8.  Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies.

Authors:  Namita A Goyal; Tahseen Mozaffar
Journal:  Curr Treat Options Neurol       Date:  2018-07-23       Impact factor: 3.598

Review 9.  Is statin-induced myositis part of the polymyositis disease spectrum?

Authors:  Jemima Albayda; Andrew L Mammen
Journal:  Curr Rheumatol Rep       Date:  2014-08       Impact factor: 4.592

10.  Differential immunohistological features of inflammatory myopathies and dysferlinopathy.

Authors:  Jae-Hwan Choi; Yeong-Eun Park; Sung-Il Kim; Jeong-Il Kim; Chang-Hoon Lee; Kyu-Hyun Park; Dae-Seong Kim
Journal:  J Korean Med Sci       Date:  2009-11-07       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.